Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603.
Yasuyuki KawamotoSatoshi YukiKentaro SawadaMichio NakamuraOsamu MutoSusumu SogabeYoshiaki ShindoAtsushi IshiguroAtsushi SatoYasushi TsujiMasayoshi DazaiHiroyuki OkudaTakashi MeguroKazuaki HaradaMari SekiguchiKazufumi OkadaYoichi M ItoYuh SakataNaoya SakamotoYoshito KomatsuPublished in: The oncologist (2022)
Although the primary endpoint was not achieved statistically, combination therapy of ramucirumab plus irinotecan showed anticancer activity and a manageable safety profile for second-line treatment of patients with advanced gastric cancer.